DEFR14A: HCW Biologics Corrects Share Count in Proxy Statement Amendment

HCW Biologics files an amendment to its proxy statement to correct a clerical error regarding the number of outstanding common shares.

Summary

• HCW Biologics Inc. filed Amendment No. 1 to its Definitive Proxy Statement on February 21, 2025, to correct the number of outstanding common shares as of February 18, 2025.
• The correction changes the number of shares from 44,540,394 to 44,544,996.
• This amendment only supersedes the disclosure on page 3 regarding who may vote at the Special Meeting and the table on page 13 showing the impact of a Reverse Stock Split at different ratios.
• The proxy statement distributed to stockholders was corrected prior to printing and does not contain the clerical error.
• The Special Meeting of Stockholders is scheduled for March 31, 2025.

Sentiment

Score: 7

Explanation: The document is a neutral correction of a clerical error, indicating attention to detail and compliance. It doesn't significantly impact the company's outlook but shows diligence.

Positives

• The company promptly corrected the error in the proxy statement.

Future Outlook

The document does not contain specific forward-looking statements beyond the scheduled Special Meeting.

Industry Context

This announcement is a routine correction to a proxy statement, which is a common occurrence for publicly traded companies.

Stakeholder Impact

• The correction ensures that shareholders have accurate information for voting decisions.

Next Steps

• Stockholders should read the amended proxy statement in conjunction with the original proxy statement before voting at the Special Meeting on March 31, 2025.

Key Dates

Keywords

proxy statement, amendment, common stock, HCW Biologics, special meeting, reverse stock split, shares outstanding